Free Trial

Ontrak (OTRK) Competitors

Ontrak logo
$0.02 -0.01 (-24.91%)
As of 09/26/2025

OTRK vs. BACK, BTTX, UPHL, OPGN, ACONW, AONC, DHACW, FMS, LFMDP, and OTRKP

Should you be buying Ontrak stock or one of its competitors? The main competitors of Ontrak include IMAC (BACK), Better Therapeutics (BTTX), UpHealth (UPHL), OpGen (OPGN), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), Fresenius Medical Care AG & Co. KGaA (FMS), LifeMD (LFMDP), and Ontrak (OTRKP). These companies are all part of the "healthcare" industry.

Ontrak vs. Its Competitors

IMAC (NASDAQ:BACK) and Ontrak (NASDAQ:OTRK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

IMAC has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

In the previous week, IMAC had 1 more articles in the media than Ontrak. MarketBeat recorded 2 mentions for IMAC and 1 mentions for Ontrak. Ontrak's average media sentiment score of 1.05 beat IMAC's score of 0.00 indicating that Ontrak is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ontrak
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IMAC has a net margin of 0.00% compared to Ontrak's net margin of -274.20%. IMAC's return on equity of 0.00% beat Ontrak's return on equity.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
Ontrak -274.20%-269.88%-128.35%

IMAC has higher earnings, but lower revenue than Ontrak.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.07-$9.42MN/AN/A
Ontrak$10.18M0.01-$25.49M-$15.810.00

Ontrak has a consensus price target of $3.00, indicating a potential upside of 13,536.36%. Given Ontrak's stronger consensus rating and higher probable upside, analysts plainly believe Ontrak is more favorable than IMAC.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ontrak
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

5.8% of IMAC shares are owned by institutional investors. Comparatively, 12.9% of Ontrak shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Comparatively, 1.9% of Ontrak shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IMAC and Ontrak tied by winning 7 of the 14 factors compared between the two stocks.

Get Ontrak News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTRK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTRK vs. The Competition

MetricOntrakMED IndustryMedical SectorNASDAQ Exchange
Market Cap$93K$4.27B$5.70B$10.43B
Dividend YieldN/A1.26%5.78%4.69%
P/E Ratio0.0026.9775.6826.32
Price / Sales0.01239.54551.24126.17
Price / CashN/A28.3325.6330.64
Price / Book0.014.7212.686.40
Net Income-$25.49M$197.51M$3.29B$273.79M
7 Day PerformanceN/A2.89%0.98%-0.22%
1 Month PerformanceN/A2.57%4.38%6.74%
1 Year PerformanceN/A23.55%65.72%27.58%

Ontrak Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTRK
Ontrak
2.6447 of 5 stars
$0.02
-24.9%
$3.00
+13,536.4%
-99.2%$93K$10.18M0.00250News Coverage
Gap Down
BACK
IMAC
N/A$0.07
-5.6%
N/A-92.7%$155K$72.05K0.00180Gap Down
BTTX
Better Therapeutics
N/A$0.00
+100.0%
N/AN/A$10KN/A0.0040Gap Up
UPHL
UpHealth
N/A$0.00
flat
N/A-99.7%$4K$130M0.001,750
OPGN
OpGen
N/AN/AN/A-100.0%$1K$2.67M0.00100
ACONW
Aclarion
N/A$0.03
+3.8%
N/AN/A$0.00$62.95K0.007Gap Down
AONC
American Oncology Network
N/A$10.64
+0.5%
N/A+138.1%$0.00$1.34B0.001,520
DHACW
Digital Health Acquisition
N/A$0.03
+30.8%
N/AN/A$0.00N/A0.00N/AGap Up
FMS
Fresenius Medical Care AG & Co. KGaA
3.4656 of 5 stars
$25.65
+1.4%
$27.80
+8.4%
+19.9%$0.00$20.63B21.031,384
LFMDP
LifeMD
N/A$23.96
+0.2%
N/A+6.4%$0.00$245.56M0.00230Dividend Cut
OTRKP
Ontrak
N/A$0.04
+75.0%
N/A-86.0%$0.00$10.84M0.00250Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OTRK) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners